We developed and validated a high specificity, affinity-purified anti-REDD1 antibody (DeYoung et al. 2008) that we applied to a clinically annotated set of primary lung adenocarcinomas (Huynh et al. 2016). This evidence concerns the gene DDIT4 and lung adenocarcinoma.